Refers to Finan, B. et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 21, 27-36 (2015) An innovative strategy that uses a well-balanced monomeric peptide triagonist to target three metabolically related hormone receptors has been developed. This strategy seems to be the most effective pharmacological approach to reverse obesity and its metabolic comorbidities in rodents and could open new ways to tackle the dual burden of obesity and diabetes mellitus in humans.
The management of patients with obesity and type 2 diabetes mellitus (T2DM) is challenging in clinical practice. The recurrent failure of lifestyle changes and available pharmacological approaches in the manage ment of these patients has led to many patients undergoing bariatric surgery and has stimulated the search for new p harmacological strategies. 1 Finan and colleagues have reported the discovery of a new agonist that simultaneously targets three key metabolically related peptide hormone receptors-the receptors for glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon ( Figure 1 ). 2 This monomeric peptide exerts a balanced agonist effect and was proved to be remarkably effective at reducing body weight, improving glucose control and reversing hepatic steatosis in various rodent models of either diet-induced or genetically d etermined obesity and/or diabetes mellitus.
Through elegant studies in which knockout mice for the individual receptors were used, Finan and colleagues were able to demonstrate that the unimolecular triagonist targeted each of the three receptors. 2 The researchers were also able to ascertain how much blocking each receptor contributed to the overall metabolic benefits of the monomeric peptide. They found that the overall metabolic efficacy of the new drug predominantly resulted from synergistic glucagon action that increased energy expenditure, GLP-1 action that reduced caloric intake and improved glucose control and GIP action that potentiated the socalled incretin effect. Interestingly, the last two actions buffer against the diabetogenic effect of the inherent glucagon-mimicking activity of the peptide. Thus, these preclinical studies in rodents suggest that this unimolecular, polypharmaceutical strategy has the potential to reverse obesity and related metabolic disorders. 2 Further studies should confirm whether this innovative pharmacological approach, which proved superior to therapy with any existing dual coagonists and best-in-class monoagonists in rodents, might be effective and safe for the treatment of obesity and T2DM in humans and thus ultimately offer a valuable pharmacological alternative to bariatric surgery. 3 The dramatic rise of the twin epidemics of T2DM and obesity is associated with increased mortality and morbidity and is one of the most important public-health challenges worldwide. 1 Striking parallel increases in the prevalence of the two entities reflect the importance of body fatness as a contributing factor to the incidence of T2DM and its complications. Despite the importance of strategies to control weight in the prevention and management of T2DM, long-term results with lifestyle or available drug interventions are generally disappointing. 1 Notably, therapeutic attempts to normalize body weight and glycaemia with single agents have generally had poor results. 1 Furthermore, most of the classic glucose-lowering agents are accompanied by weight gain, which increases the challenge of managing most individuals with T2DM who are overweight or have obesity. 1 Incretin-based therapies are increasingly being used in clinical practice for the manage ment of T2DM. 4 The dipeptidyl peptidase 4 (DPP-4) enzyme rapidly degrades GLP-1 and GIP, two gastrointestinal hormones that potentiate insulin secretion in response to a meal. 4 Therapeutic approaches for enhancing incretin action include degradation-resistant GLP-1 receptor agonists (incretin mimetics) and inhibitors of DPP-4 activity (incretin enhancers). 4 In addition to its incretin effect, GLP-1 suppresses glucagon secretion, inhibits gastric emptying and reduces appetite and food intake. 5 Both oral DPP-4 inhibitors (known as gliptins) and injectable GLP-1 receptor agonists exert a glucose-lowering effect with no or only a minimal risk of hypoglycaemia, with the injectable agents being more potent than the oral compounds. 4 Furthermore, DPP-4 inhibitors are weight-neutral, whereas GLP-1 receptor agonists reduce body weight. 4 However, the amount of weight lost is generally moderate and cannot compete with the drastic weight reduction Nature Reviews | Endocrinology 
''
…this … strategy has the potential to reverse obesity and related metabolic disorders '' www.nature.com/nrendo NEWS & VIEWS induced by bariatric surgery. The benefits of bariatric surgery, however, extend well beyond weight loss and include dramatic improvement of T2DM. By mimick ing the profound changes in the enteroendocrine responses that are secondary to changes in gastro intestinal anatomy, drugs based on gut hormones represent an exciting possibility for the treatment of T2DM and obesity. 1, 3 Emerging data from preclinical studies supports the feasibility of using two or more agonists, or single co-agonists, for the t reatment of obesity and T2DM. 3 The therapeutic value of the triagonist developed by Finan and colleagues cannot be accurately determined from these preclinical studies. One crucial feature that needs to be established before using such a triagonist in humans is a well-balanced stimulation of the glucagon receptor. Indeed, glucagon is a counter-regulatory hormone that has a potent hypergly caemic effect, as it increases hepatic glucose output through the stimulation of both glycogenolysis and gluconeogenesis. 6 Some experimental data suggest that suppression or inactivation of glucagon might provide therapeutic advantages over insulin monotherapy. 6 Many attempts have been made to inhibit glucagon secretion and/or action, with the aim of improving glucose control in T2DM, but without obvious success so far (except for incretin-based therapies 7 ). The activation of the glucagon receptor proposed by Finan and colleagues drastically contrasts with previous attempts to inhibit the action of glucagon. The theory is that glucagon could have some beneficial activities, whereas its diabetogenic effects might be counteracted by the co-activation of GLP-1 and GIP receptors. Glucagon, at least partly by inhibiting secretion of orexin A, might increase energy expenditure and thus promote weight loss, as shown in animals and humans, irrespective of changes in levels of glucose or insulin. 8 Furthermore, data from the past 2 years have shown that coadministration of GLP-1 during glucagon infusion in humans results in increased energy expenditure, reduction in food intake and amelioration of hyperglycaemia. 9, 10 Thus, GLP-1 protects against glucagon-induced hyperglycaemia and the glucagon-induced increase in energy expenditure is maintained. These observations support the concept of GLP-1 and glucagon dual agonism as a possible treatment for obesity and T2DM. Of note, GIP action to potentiate the incretin effect, as present in the new triagonist, could also contribute to the buffer against the diabetogenic effect of inherent stimulation of the glucagon receptor. 5 Finan and colleagues are confident that the glucagon activity of the triagonist can be selectively fine-tuned with minimal structural or chemical changes. 2 If this fine-tuning is possible, the ability to choose among several options that differ in their inherent molecular pharmacology would certainly increase the likelihood of success in humans.
The pharmacological outcomes of targeting a particular pathway in humans are often difficult to predict from results in animal models and safety issues are always critical in humans. Cardiovascular safety is becoming a major concern for the development of any new antidiabetic agents and glucagon is known to have some cardiovascular effects in humans that still need to be investigated. Furthermore, humans have a different metabolic profile to that of rodents 5 and many promising strategies to treat obesity and/or diabetes mellitus in rodents are not successful in humans. 1 Whether novel mechanisms identified in preclinical studies, such as that by Finan and colleagues, 2 have potential translational relevance for the treatment of human disease requires extensive research.
